These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22472915)

  • 21. Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
    Folse HJ; Goswami D; Rengarajan B; Budoff M; Kahn R
    Atherosclerosis; 2014 Sep; 236(1):154-61. PubMed ID: 25050538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
    Reckless J; Davies G; Tunceli K; Hu XH; Brudi P
    Value Health; 2010; 13(6):726-34. PubMed ID: 20561328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification.
    Marquina C; Morton J; Zomer E; Talic S; Lybrand S; Thomson D; Liew D; Ademi Z
    Value Health; 2023 Apr; 26(4):498-507. PubMed ID: 36442832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease.
    Akyea RK; Kai J; Qureshi N; Iyen B; Weng SF
    Heart; 2019 Jul; 105(13):975-981. PubMed ID: 30988003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals.
    van Kempen BJ; Spronk S; Koller MT; Elias-Smale SE; Fleischmann KE; Ikram MA; Krestin GP; Hofman A; Witteman JC; Hunink MG
    J Am Coll Cardiol; 2011 Oct; 58(16):1690-701. PubMed ID: 21982314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The Prediction Model of Cardiovascular Events Among the Russian Population: Methodological Aspects].
    Kontsevaya AV; Shalnova SA; Suvorova EI; Balanova YA; Evstifeeva SE; Imaeva AE; Kapustina AV; Deev AD; Karpov YA; Ostroumova OD; Ageev FT; Blinkov OS; Zinchuk IY; Repekto KA; Boytsov S A
    Kardiologiia; 2016 Dec; 56(12):54-62. PubMed ID: 28290805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.
    Stam-Slob MC; van der Graaf Y; Greving JP; Dorresteijn JA; Visseren FL
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
    De Smedt D; Kotseva K; De Bacquer D; Wood D; De Backer G; Dallongeville J; Seppo L; Pajak A; Reiner Z; Vanuzzo D; Georgiev B; Gotcheva N; Annemans L
    Eur Heart J; 2012 Nov; 33(22):2865-72. PubMed ID: 22843446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP; Visseren FL; de Wit GA; Algra A
    BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
    Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
    Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS.
    Palmer SJ; Brady AJ; Ratcliffe AE
    Int J Clin Pract; 2003 Nov; 57(9):792-800. PubMed ID: 14686571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective.
    Kunz WG; Hunink MG; Sommer WH; Beyer SE; Meinel FG; Dorn F; Wirth S; Reiser MF; Ertl-Wagner B; Thierfelder KM
    Stroke; 2016 Nov; 47(11):2797-2804. PubMed ID: 27758942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.